Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 6, 2016. The report details the presentation of further data from the pivotal Phase III FULFIL study regarding an investigational closed triple combination therapy (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of chronic obstructive pulmonary disease (COPD). The data was presented at the European Respiratory Society International Congress in London.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical study update and does not contain financial statements.
Material Changes and Clinical Results
The FULFIL study compared once-daily FF/UMEC/VI against twice-daily Symbicort Turbohaler (budesonide/formoterol) in patients with advanced COPD. Key results include:
- Lung Function: At 24 weeks, FF/UMEC/VI showed a statistically significant improvement in trough FEV1 of 171mL compared to the comparator. At 52 weeks, the improvement was 179mL.
- Quality of Life: At 24 weeks, the mean change in St George's Respiratory Questionnaire (SGRQ) total score was -6.6 units for FF/UMEC/VI versus -4.3 units for the comparator (difference of -2.2 units, p<0.001). 50% of patients on FF/UMEC/VI achieved the minimum clinically important difference versus 41% on the comparator.
- Exacerbations: FF/UMEC/VI demonstrated a 35% reduction in the annual rate of moderate/severe exacerbations at 24 weeks (p=0.002) and a 44% reduction in the 52-week subset (p=0.006) compared to budesonide/formoterol.
- Safety: The safety profile was consistent with known profiles of individual medicines. The most common adverse events were nasopharyngitis, headache, and COPD worsening. Serious adverse events occurred in 5.4% (FF/UMEC/VI) vs 5.7% (comparator) at 24 weeks, and 10.0% vs 12.7% at 52 weeks.
Guidance, Outlook, and Risks
Regulatory Outlook: GSK plans to submit regulatory applications for the closed triple combination therapy for COPD in the US and Europe by the end of 2016. The therapy is not currently approved for use anywhere in the world.
Management Commentary: GSK executives highlighted that reducing exacerbations is a priority for physicians and that the significant reductions observed support the clinical value of a convenient, once-daily triple therapy option. Innoviva, Inc. noted the results confirm superiority over dual therapy on key measures.
Risks and Contingencies: The filing includes standard cautionary statements regarding forward-looking statements. Risks include the potential for actual results to differ from projections due to regulatory delays, clinical study outcomes, and commercialization challenges. Innoviva specifically noted risks related to royalty revenue dependence and third-party collaboration.
Investor Verification Checklist
- Verify the timeline for regulatory submissions in the US and Europe, currently targeted for the end of 2016.
- Monitor the ongoing IMPACT study, expected to complete in 2017, which compares FF/UMEC/VI against other dual therapies.
- Review the safety data regarding pneumonia incidence (1.0% vs 0.3% at 24 weeks; 1.9% vs 1.8% at 52 weeks) in the context of regulatory review.
- Assess the commercial partnership structure with Innoviva, Inc., including royalty revenue streams and economic interests in future payments.
- Confirm the competitive landscape against Symbicort Turbohaler and other existing COPD treatments.